Esperion Therapeutics, Inc. Exhibit
EX-99.1 2 a18-21191_1ex99d1.htm EX-99.1 Exhibit 99.1     Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study   ·  Bempedoic Acid / Ezetimibe Combo Pill Achieved an Additional 35%  LDL-C Lowering in Patients on Maximally Tolerated Statins ·  35% LDL-C Lowering Provides Potential for More Than 6 Million U.S. Patients to Reach LDL-C Levels of 70 mg/dL ·  Bempedoic Acid / Ezetimibe Combo Pill Appeared to be as Safe and Well-Tolerated as Ezetimibe Alone ·  Provided an Additional 34% hsCRP Reduction ·  Bempedoic Acid / Ezetimibe Combo Pill Achieved an Additional 43% LDL-C lowering in Patients Considered Statin Intolerant (post-hoc analysis) ·  Conference Call and Webcast on Monday,…
To view the full exhibit click here

About Esperion Therapeutics,Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.